| 标题： | 肝细胞癌全程管理中国专家共识(2023版) |
| title： | Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023 edition) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 医生 |
| Guide users： | Doctors |
| 证据分级方法： | 共识中的推荐意见共分5个级别，分别基于6个证据等级，见表1、2。 表1 循证医学证据等级 证据级别 描述 Ⅰa 证据源于对多项随机对照研究的meta分析结果 Ⅰb 证据源于至少一项设计良好的随机对照研究结果 Ⅱa 证据源于至少一项设计良好的前瞻性非随机对照研究结果 Ⅱb 证据源自至少一项设计良好的其他类型干预性临床研究结果 Ⅲ 证据源于设计良好的非干预性研究，如描述性研究、相关性研究等 Ⅳ 证据源于专家委员会报告或权威专家的临床经验报道 表2 专家推荐意见级别 证据级别 描述 A 良好的科学证据提示该医疗行为带来明确获益；建议医师对患者实施该医疗行为 B 现有证据表明该医疗行为可带来中度获益，超过其潜在风险；医师可建议或对患者实施该医疗行为 C 现有证据表明该医疗行为可能获益较小，或获益与风险接近；医师可根据患者个体情况有选择地向患者建议和实施该医疗行为 D 现有证据表明该医疗行为无获益，或其潜在风险超过获益；医师不宜向患者实施该医疗行为 I 缺乏科学证据，或现有证据无法评价该医疗行为的获益与风险；医师应帮助患者理解该医疗行为存在的不确定性 |
| Evidence grading method： | Table 1. Level of evidence in evidence-based medicine Level of evidence Description Ⅰa The evidence comes from a meta-analysis of multiple randomized controlled studies Ⅰb The evidence comes from at least one well-designed randomized controlled study Ⅱa The evidence comes from at least one well-designed prospective non-randomized controlled study Ⅱb The evidence comes from at least one well-designed interventional clinical study of other types Ⅲ The evidence comes from well-designed non-interventional studies, such as descriptive and correlation studies. Ⅳ The evidence comes from reports of the expert committee or clinical experience reports of authoritative experts Table 2. Levels of expert recommendations Level of evidence Description A Good scientific evidence suggests that the medical treatment confers clear benefits; it is recommended that physicians perform the medical treatment on patients. B Existing evidence shows that the medical treatment can confer moderate benefits that outweigh its potential risks; physicians can recommend or perform the medical treatment on patients. C Existing evidence shows that the medical treatment may have little benefit, or the benefit is close to the risk; physicians can selectively recommend and perform the medical treatment on patients according to their individual condition. D Existing evidence shows that the medical treatment has no benefit, or its potential risks outweigh the benefits; it is not appropriate for physicians to perform the medical treatment on patients. I There is a lack of scientific evidence, or existing evidence cannot be used to evaluate the benefits and risks of the medical treatment; physicians should help the patients understand the uncertainty of the medical treatment. |
| 制定单位： | 中国医师协会肝癌专业委员会 |
| Formulating unit： | Chinese Association of Liver Cancer and Chinese Medical Doctor Association |
| 注册时间： | 2023-05-26 |
| Registration time： | |
| 注册编号： | PREPARE-2023CN365 |
| Registration number： | |
| 指南制订的目的： | 为更好地指导肝细胞癌的全程管理，中国医师协会肝癌专业委员会组织国内相关领域专家制定《肝癌全程管理中国专家共识(2023版)》，以期为从事HCC相关临床工作的同道提供理论和实践参考。 |
| Purpose of the guideline： | To better guide the whole-course management of hepatocellular carcinoma, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association organized domestic experts in relevant fields to develop the "Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023 edition)", in order to provide theoretical and practical references for colleagues engaged in HCC related clinical work. |
